Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

NEXT Virginia, LLC

Neither a doctor nor a teaching hospital

Research payments

$2,647,639

544 payments

Through program year 2025, NEXT Virginia, LLC is reported as receiving $2,647,639 in research payments, across 544 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $1,362,316 196
2024 Research $883,705 230
2023 Research $401,618 118

Breakdown

Who paid Research payments · program years 2023–2025
  1. Daiichi Sankyo Inc. $767,454 238 payments
  2. Chugai Pharmaceutical Co., Ltd. $714,914 183 payments
  3. Exelixis Inc. $437,298 28 payments
  4. Genentech, Inc. $175,674 42 payments
  5. BeOne Medicines USA, Inc. $153,921 11 payments
  6. Merck Sharp & Dohme Corporation $118,200 2 payments
  7. Taiho Oncology, Inc. $114,201 29 payments
  8. BeOne Medicines Ltd. $76,265 4 payments
  9. Astellas Pharma Global Development $40,449 3 payments
  10. BeiGene, Ltd. $31,966 3 payments
Studies the money was for Research payments · program years 2023–2025
  1. A PHASE Ia/Ib OPEN LABEL, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF ROSE12 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS $719,830 196 payments
  2. Ds1103-074 $667,086 171 payments
  3. A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors $437,298 28 payments
  4. A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors $211,089 14 payments
  5. A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors $170,758 29 payments
  6. Ds3201-324 $100,368 67 payments
  7. A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations $86,765 19 payments
  8. A Phase Ib,II Combination Trial of the PI3K- Selective Inhibitor GSK2636771 with Pembrolizumab for PTEN-deficient Metastatic Castration-Resistant Prostate Cancer and Metastatic Endometrial Cancer Patients $78,800 1 payment
  9. A Phase 1b Study of Gilteritinib in Participants with Locally Advanced or Metastatic NSCLC with ALK Rearrangement After Prior Treatment with an ALK Inhibitor $40,449 3 payments
  10. A Phase 1,2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction GEJ, or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and,or the ChecKpoint Inhibitor Pembrolizumab. TWINPEAK Study $39,400 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record